Clinical application of a cytochemical bioassay for the determination of thyroid stimulating hormone.
Thyroid stimulating hormone (TSH) was measured using a highly sensitive cytochemical bioassay (CBA) technique in normal subjects, in patients with Graves' disease (untreated and treated) and in patients with euthyroid goiter and negative thyrotropin-releasing hormone (TRH)-test. Plasma TSH levels of normal subjects and of subjects with untreated Graves' disease were reduced after the plasma had been incubated with a specific antibody to human TSH, indicating that the thyroid stimulating substance measured with this assay was likely to be TSH. Basal TSH levels in patients with Graves' disease and in a special group of patients with euthyroid goiter and negative TRH test were low but detectable. They did not rise after TRH administration. Increased TSH release (4.5- to 10-fold) after TRH stimulation was demonstrated, however, in two formerly hyperthyroid patients after treatment. This increase was not detected by radioimmunoassay (RIA) due to limited sensitivity.
D000368:Aged; D000818:Animals; D005260:Female; D006042:Goiter / Q000097:blood*; D006111:Graves Disease / Q000097:blood* / Q000188:drug therapy; D006168:Guinea Pigs; D006651:Histocytochemistry; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D013965:Thyroidectomy; D013972:Thyrotropin / Q000097:blood*; D013973:Thyrotropin-Releasing Hormone
D007457:Iodine Radioisotopes; D013973:Thyrotropin-Releasing Hormone; D013972:Thyrotropin